<DOC>
	<DOCNO>NCT02271984</DOCNO>
	<brief_summary>This phase I , open-label , randomize , 5 period , crossover , single-center trial . The purpose trial assess relative bio-availability L-praziquantel ( L-PZQ [ MSC2499550A ] ) oral dispersible tablet ( ODT ) formulation ( 150 mg ) versus current market praziquantel ( PZQ ) ( cysticideÂ® 500 mg ) formulation healthy male volunteer .</brief_summary>
	<brief_title>Relative Bioavailability Trial L-Praziquantel Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Healthy male age 1855 year age ( inclusive screening ) Male subject partner childbearing potential must vasectomy use acceptable method birth control ( , condom ) donate sperm , 90 day last dose trial medication Written inform consent prior trial related procedure Have body weight great ( &gt; ) 55.0 kilogram ( kg ) less ( &lt; ) 95.0 kg body mass index ( BMI ) 18.5 29.9 kilogram per square meter ( kg/m^2 ) ( inclusive ) Able communicate well Investigator , understand protocol requirement restriction , willing comply requirement entire trial Nonsmoker ( = 0 cigarette , pipe , cigar others ) since least 3 month Electrocardiogram ( ECG ) recording ( 12lead ) without sign clinically relevant pathology particular QTc ( Bazett ) &lt; 450 millisecond ( m ) Vital sign ( systolic diastolic blood pressure , pulse ) supine position body temperature within normal range show clinically relevant deviation judge medical Investigator Any surgical medical condition , include finding medical history prestudy assessment , significant disease , opinion Investigator , constitute risk contraindication participation subject study could interfere study objective , conduct evaluation History surgery gastrointestinal tract ( GI ) , history GI tract disease , acute GI tract infection last 2 week , could influence GI absorption and/or motility accord Investigator 's opinion Any clinically relevant abnormality safety laboratory parameter judge Investigator Have positive result serology examination Hepatitis B surface antigen ( HBsAg ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) Allergy : ascertain presumptive hypersensitivity active drug substance and/or formulation ingredient ; history anaphylaxis drug allergic reaction general , Investigator considers may affect outcome trial History presence drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine ( phenylcyclohexalpiperidine ) , tetrahydrocannabinol , tricyclic antidepressant , methadone , methamphetamine , oxycodone propoxyphene ) alcohol abuse screen admission define Investigator Loss donation 400 milliliter ( mL ) blood within 90 day prior first PZQ administration Administration investigational product use investigational device within60 day prior first PZQ administration Subjects use drug may affect pharmacokinetics ( PK ) PZQ 14 day dose last PK sample , example , phenytoin , barbiturate , primidone , carbamazapine , oxcarbazepine , topiramate , felbamate , rifampicin , nelfinavir , ritonavir , griseofulvin , oral ketoconazole , discretion Investigator Consumption substance know potent inhibitor inducer cytochrome P450 enzyme ( CYP P450s ) grapefruit juice , grapefruit juice contain product , herbal remedy dietary supplement contain St. John 's Wort , 2 week dose Unlikely comply protocol requirement , instruction trialrelated restriction , example , uncooperative attitude , inability return followup visit , improbability complete trial Nonacceptance study breakfast ( example , vegetarian , vegan subject follow special diet ) Excessive consumption beverage contain xanthine ( &gt; 5 cup ) coffee day , equivalent inability stop consume caffeine 48 hour prior drug administration discharge clinic Subject Investigator SubInvestigator , research assistant , pharmacist , trial coordinator , staff relative thereof directly involve conduct trial Vulnerable subject ( example , person keep detention ) Legal incapacity limit legal capacity</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Praziquantel</keyword>
	<keyword>L-PZQ</keyword>
	<keyword>PZQ</keyword>
	<keyword>MSC2499550A</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>